Pegasus Asset Management Inc. Acquires 324 Shares of Merck & Co., Inc. (NYSE:MRK)

Pegasus Asset Management Inc. increased its holdings in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 0.9% in the first quarter, Holdings Channel.com reports. The firm owned 35,180 shares of the company’s stock after purchasing an additional 324 shares during the quarter. Merck & Co., Inc. makes up 1.8% of Pegasus Asset Management Inc.’s holdings, making the stock its 22nd largest holding. Pegasus Asset Management Inc.’s holdings in Merck & Co., Inc. were worth $4,642,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of MRK. Cross Staff Investments Inc grew its stake in shares of Merck & Co., Inc. by 3.5% during the 4th quarter. Cross Staff Investments Inc now owns 6,710 shares of the company’s stock worth $732,000 after acquiring an additional 225 shares in the last quarter. PFW Advisors LLC bought a new position in shares of Merck & Co., Inc. during the 1st quarter worth approximately $212,000. Dynamic Advisor Solutions LLC grew its stake in shares of Merck & Co., Inc. by 6.0% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 77,833 shares of the company’s stock worth $10,270,000 after acquiring an additional 4,433 shares in the last quarter. Kennedy Investment Group grew its stake in shares of Merck & Co., Inc. by 16.0% during the 4th quarter. Kennedy Investment Group now owns 2,564 shares of the company’s stock worth $280,000 after acquiring an additional 354 shares in the last quarter. Finally, Schear Investment Advisers LLC boosted its holdings in shares of Merck & Co., Inc. by 16.0% in the 4th quarter. Schear Investment Advisers LLC now owns 3,233 shares of the company’s stock valued at $352,000 after buying an additional 445 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

MRK has been the subject of several recent analyst reports. Wells Fargo & Company increased their price objective on Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a report on Wednesday, March 27th. Argus raised Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, June 5th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price objective on shares of Merck & Co., Inc. in a report on Tuesday, June 18th. Berenberg Bank increased their price objective on Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a report on Monday, April 8th. Finally, Truist Financial increased their price objective on Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a report on Friday, April 26th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $133.00.

View Our Latest Stock Report on MRK

Merck & Co., Inc. Trading Up 0.2 %

Shares of Merck & Co., Inc. stock opened at $126.08 on Wednesday. The firm has a 50-day moving average of $128.99 and a 200-day moving average of $125.39. The stock has a market cap of $319.34 billion, a PE ratio of 140.09, a PEG ratio of 2.43 and a beta of 0.38. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $134.63. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.21 billion. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. Merck & Co., Inc.’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.40 earnings per share. As a group, sell-side analysts forecast that Merck & Co., Inc. will post 8.62 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, July 8th. Stockholders of record on Monday, June 17th were given a $0.77 dividend. The ex-dividend date was Monday, June 17th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.44%. Merck & Co., Inc.’s payout ratio is presently 342.22%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.